Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients
Identifieur interne : 001435 ( Main/Exploration ); précédent : 001434; suivant : 001436Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients
Auteurs : Pramote Tragulpiankit [Thaïlande] ; Suvatna Chulavatnatol ; Ticha Rerkpattanapipat [Thaïlande] ; Suchela Janwityanujit [Thaïlande] ; Suthatip Somjarit ; Uamporn SirikhedgonSource :
- International Journal of Rheumatic Diseases [ 1756-1841 ] ; 2012-06.
English descriptors
- Teeft :
- Ade, Adverse drug event, Adverse drug events, Adverse drug reactions, Adverse event, Adverse events, Adverse reactions, Ambulatory, Ambulatory care, Ambulatory patients, Antirheumatic drug, Best pract, Cardiovascular agents, Causality, Causality assessment, Clin epidemiol, Clin rheumatol, Coexisting diseases, Current visit, Direct patient interview, Disease state, Dmards, Drug change, Drug events, Drug groups, Elderly patients, Frequent drug groups, Gastrointestinal tract, High rate, Higher rate, Hosp pharm, International journal, Last hospital visit, Liver injuries, Lower prevalence, Mahidol university, Nsaid, Oral contraceptives, Oral corticosteroids, Organ systems, Osteoarthritis, Other studies, Other treatment, Pathophysiologic approach, Patient education, Patient outcome, Permanent harm, Pharmacist, Preventability, Preventability assessment, Preventable, Preventable ades, Ramathibodi hospital, Research pharmacist, Rheumatic, Rheumatic disease, Rheumatic diseases, Rheumatoid arthritis, Rheumatologist, Rheumatology clinics, Severity level, Study period, Systematic review, Therapeutic drug monitoring.
Abstract
Aim: We aimed to determine the prevalence and characteristics of adverse drug events (ADE) in rheumatoid arthritis (RA) and (osteoarthritis) OA patients. Method: A cross‐sectional study at rheumatology clinics, was performed by random selection of RA and OA out‐patients by a research pharmacist. All suspected ADEs occurring during the last hospital visit and the subjects were identified by retrospective chart review and direct patient interview. ADE characteristics, including causative drug groups, affected organ severity and patient outcomes, were recorded. Results: One hundred and forty‐three patients consisting of 129 RA and 14 OA were recruited. The patients’ mean ages were 54.3 ± 14.3 years and 121 (84.6%) patients were female. A total of 68 ADEs were detected in 51 patients. The prevalence and rate of ADE were 35.7% and 47.6 events per 100 patients, respectively. Thirty out of 68 ADEs (44.1%) were preventable. Disease‐modifying anti‐rheumatic drugs and non‐steroidal anti‐inflammatory drugs resulted in ADEs by 41 (59.4%) and 10 (14.5%) events, respectively. Common affected organs were skin, gastrointestinal tract and eyes which accounted for 20 (29.4%), 18 (26.5%) and eight events (11.6%), respectively. Continuation of the suspected drug was noted in 42 ADEs (61.8%), classified as severity level 1 and 2a‐b, and 43 ADEs (63.2%) were completely or partially resolved during the study period. Conclusion: ADEs are common in RA and OA patients with prevalence of 35.7%. High exposure to potentially harmful drugs might explain the higher rate of ADE in these patients.
Url:
DOI: 10.1111/j.1756-185X.2012.01716.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000220
- to stream Istex, to step Curation: 000220
- to stream Istex, to step Checkpoint: 000444
- to stream Main, to step Merge: 001436
- to stream Main, to step Curation: 001435
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients</title><author><name sortKey="Tragulpiankit, Pramote" sort="Tragulpiankit, Pramote" uniqKey="Tragulpiankit P" first="Pramote" last="Tragulpiankit">Pramote Tragulpiankit</name></author><author><name sortKey="Chulavatnatol, Suvatna" sort="Chulavatnatol, Suvatna" uniqKey="Chulavatnatol S" first="Suvatna" last="Chulavatnatol">Suvatna Chulavatnatol</name></author><author><name sortKey="Rerkpattanapipat, Ticha" sort="Rerkpattanapipat, Ticha" uniqKey="Rerkpattanapipat T" first="Ticha" last="Rerkpattanapipat">Ticha Rerkpattanapipat</name></author><author><name sortKey="Janwityanujit, Suchela" sort="Janwityanujit, Suchela" uniqKey="Janwityanujit S" first="Suchela" last="Janwityanujit">Suchela Janwityanujit</name></author><author><name sortKey="Somjarit, Suthatip" sort="Somjarit, Suthatip" uniqKey="Somjarit S" first="Suthatip" last="Somjarit">Suthatip Somjarit</name></author><author><name sortKey="Sirikhedgon, Uamporn" sort="Sirikhedgon, Uamporn" uniqKey="Sirikhedgon U" first="Uamporn" last="Sirikhedgon">Uamporn Sirikhedgon</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:EF7AAC0BB24AD3FD0501EC59F9AAF459E502E199</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1111/j.1756-185X.2012.01716.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-F45C55KV-V/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000220</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000220</idno><idno type="wicri:Area/Istex/Curation">000220</idno><idno type="wicri:Area/Istex/Checkpoint">000444</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000444</idno><idno type="wicri:doubleKey">1756-1841:2012:Tragulpiankit P:adverse:drug:events</idno><idno type="wicri:Area/Main/Merge">001436</idno><idno type="wicri:Area/Main/Curation">001435</idno><idno type="wicri:Area/Main/Exploration">001435</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients</title><author><name sortKey="Tragulpiankit, Pramote" sort="Tragulpiankit, Pramote" uniqKey="Tragulpiankit P" first="Pramote" last="Tragulpiankit">Pramote Tragulpiankit</name><affiliation></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Thaïlande</country></affiliation></author><author><name sortKey="Chulavatnatol, Suvatna" sort="Chulavatnatol, Suvatna" uniqKey="Chulavatnatol S" first="Suvatna" last="Chulavatnatol">Suvatna Chulavatnatol</name><affiliation><wicri:noCountry code="no comma">Faculty of Pharmacy</wicri:noCountry></affiliation></author><author><name sortKey="Rerkpattanapipat, Ticha" sort="Rerkpattanapipat, Ticha" uniqKey="Rerkpattanapipat T" first="Ticha" last="Rerkpattanapipat">Ticha Rerkpattanapipat</name><affiliation wicri:level="1"><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Faculty of Medicine, Allergy Immunology and Rheumatology Unit, Ramathibodi Hospital, Mahidol University, Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation></author><author><name sortKey="Janwityanujit, Suchela" sort="Janwityanujit, Suchela" uniqKey="Janwityanujit S" first="Suchela" last="Janwityanujit">Suchela Janwityanujit</name><affiliation wicri:level="1"><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Faculty of Medicine, Allergy Immunology and Rheumatology Unit, Ramathibodi Hospital, Mahidol University, Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation></author><author><name sortKey="Somjarit, Suthatip" sort="Somjarit, Suthatip" uniqKey="Somjarit S" first="Suthatip" last="Somjarit">Suthatip Somjarit</name><affiliation><wicri:noCountry code="no comma">Faculty of Pharmacy</wicri:noCountry></affiliation></author><author><name sortKey="Sirikhedgon, Uamporn" sort="Sirikhedgon, Uamporn" uniqKey="Sirikhedgon U" first="Uamporn" last="Sirikhedgon">Uamporn Sirikhedgon</name><affiliation><wicri:noCountry code="no comma">Faculty of Pharmacy</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">International Journal of Rheumatic Diseases</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES</title><idno type="ISSN">1756-1841</idno><idno type="eISSN">1756-185X</idno><imprint><biblScope unit="vol">15</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="315">315</biblScope><biblScope unit="page" to="321">321</biblScope><biblScope unit="page-count">7</biblScope><date type="published" when="2012-06">2012-06</date></imprint><idno type="ISSN">1756-1841</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1756-1841</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Ade</term><term>Adverse drug event</term><term>Adverse drug events</term><term>Adverse drug reactions</term><term>Adverse event</term><term>Adverse events</term><term>Adverse reactions</term><term>Ambulatory</term><term>Ambulatory care</term><term>Ambulatory patients</term><term>Antirheumatic drug</term><term>Best pract</term><term>Cardiovascular agents</term><term>Causality</term><term>Causality assessment</term><term>Clin epidemiol</term><term>Clin rheumatol</term><term>Coexisting diseases</term><term>Current visit</term><term>Direct patient interview</term><term>Disease state</term><term>Dmards</term><term>Drug change</term><term>Drug events</term><term>Drug groups</term><term>Elderly patients</term><term>Frequent drug groups</term><term>Gastrointestinal tract</term><term>High rate</term><term>Higher rate</term><term>Hosp pharm</term><term>International journal</term><term>Last hospital visit</term><term>Liver injuries</term><term>Lower prevalence</term><term>Mahidol university</term><term>Nsaid</term><term>Oral contraceptives</term><term>Oral corticosteroids</term><term>Organ systems</term><term>Osteoarthritis</term><term>Other studies</term><term>Other treatment</term><term>Pathophysiologic approach</term><term>Patient education</term><term>Patient outcome</term><term>Permanent harm</term><term>Pharmacist</term><term>Preventability</term><term>Preventability assessment</term><term>Preventable</term><term>Preventable ades</term><term>Ramathibodi hospital</term><term>Research pharmacist</term><term>Rheumatic</term><term>Rheumatic disease</term><term>Rheumatic diseases</term><term>Rheumatoid arthritis</term><term>Rheumatologist</term><term>Rheumatology clinics</term><term>Severity level</term><term>Study period</term><term>Systematic review</term><term>Therapeutic drug monitoring</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Aim: We aimed to determine the prevalence and characteristics of adverse drug events (ADE) in rheumatoid arthritis (RA) and (osteoarthritis) OA patients. Method: A cross‐sectional study at rheumatology clinics, was performed by random selection of RA and OA out‐patients by a research pharmacist. All suspected ADEs occurring during the last hospital visit and the subjects were identified by retrospective chart review and direct patient interview. ADE characteristics, including causative drug groups, affected organ severity and patient outcomes, were recorded. Results: One hundred and forty‐three patients consisting of 129 RA and 14 OA were recruited. The patients’ mean ages were 54.3 ± 14.3 years and 121 (84.6%) patients were female. A total of 68 ADEs were detected in 51 patients. The prevalence and rate of ADE were 35.7% and 47.6 events per 100 patients, respectively. Thirty out of 68 ADEs (44.1%) were preventable. Disease‐modifying anti‐rheumatic drugs and non‐steroidal anti‐inflammatory drugs resulted in ADEs by 41 (59.4%) and 10 (14.5%) events, respectively. Common affected organs were skin, gastrointestinal tract and eyes which accounted for 20 (29.4%), 18 (26.5%) and eight events (11.6%), respectively. Continuation of the suspected drug was noted in 42 ADEs (61.8%), classified as severity level 1 and 2a‐b, and 43 ADEs (63.2%) were completely or partially resolved during the study period. Conclusion: ADEs are common in RA and OA patients with prevalence of 35.7%. High exposure to potentially harmful drugs might explain the higher rate of ADE in these patients.</div></front></TEI><affiliations><list><country><li>Thaïlande</li></country></list><tree><noCountry><name sortKey="Chulavatnatol, Suvatna" sort="Chulavatnatol, Suvatna" uniqKey="Chulavatnatol S" first="Suvatna" last="Chulavatnatol">Suvatna Chulavatnatol</name><name sortKey="Sirikhedgon, Uamporn" sort="Sirikhedgon, Uamporn" uniqKey="Sirikhedgon U" first="Uamporn" last="Sirikhedgon">Uamporn Sirikhedgon</name><name sortKey="Somjarit, Suthatip" sort="Somjarit, Suthatip" uniqKey="Somjarit S" first="Suthatip" last="Somjarit">Suthatip Somjarit</name></noCountry><country name="Thaïlande"><noRegion><name sortKey="Tragulpiankit, Pramote" sort="Tragulpiankit, Pramote" uniqKey="Tragulpiankit P" first="Pramote" last="Tragulpiankit">Pramote Tragulpiankit</name></noRegion><name sortKey="Janwityanujit, Suchela" sort="Janwityanujit, Suchela" uniqKey="Janwityanujit S" first="Suchela" last="Janwityanujit">Suchela Janwityanujit</name><name sortKey="Rerkpattanapipat, Ticha" sort="Rerkpattanapipat, Ticha" uniqKey="Rerkpattanapipat T" first="Ticha" last="Rerkpattanapipat">Ticha Rerkpattanapipat</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001435 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001435 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:EF7AAC0BB24AD3FD0501EC59F9AAF459E502E199
|texte= Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients
}}
| This area was generated with Dilib version V0.6.33. |  |